Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

Core Insights - Zevra Therapeutics, Inc. has appointed Justin Renz as Chief Financial Officer, effective March 9, 2026, bringing over 25 years of financial leadership experience in the biopharmaceutical industry [1][2] Company Overview - Zevra Therapeutics is a commercial-stage company focused on providing therapies for rare diseases, with its lead product targeting Niemann-Pick disease type C, a rare neurodegenerative disorder [4] - The company aims to broaden access through geographic expansion and has a pipeline of rare disease programs, emphasizing its patient-centric values of accountability, integrity, innovation, and courage [4] Leadership Background - Justin Renz has a strong track record in the biopharmaceutical sector, having previously served as Chief Financial & Operations Officer at Ardelyx, where he played a key role in launching two first-in-class medicines [2] - Renz also held leadership positions at Correvio Pharma, Karyopharm Pharmaceuticals, and Zalicus Inc., showcasing extensive experience in capital markets and strategic transactions [2][3]